Pitsikakis Konstantinos, DeJong Diederick, Kitsos-Kalyvianakis Konstantinos, Mamalis Marios Evangelos, Quaranta Michela, Shavee Aishath, Wahab Alina, Thangavelu Amudha, Broadhead Timothy, Nugent David, Kalampokis Evangelos, Laios Alexandros
Department of Gynaecologic Oncology, ESGO Centre of Excellence for ovarian cancer surgery, St James's University Hospital, Leeds, UK.
Information Systems Lab, Department of Business Administration, University of Macedonia, Thessaloniki, Greece.
Cancer Control. 2024 Jan-Dec;31:10732748241285480. doi: 10.1177/10732748241285480.
Cytoreductive surgery is critical for optimal tumor clearance in advanced epithelial ovarian cancer (EOC). Despite best efforts, some patients may experience R2 (>1 cm) resection, while others may not undergo surgery at all. We aimed to compare outcomes between advanced EOC patients undergoing R2 resection and those who had no surgery.
Retrospective data from 51 patients with R2 resection were compared to 122 patients with no surgery between January 2015 and December 2019 at a UK tertiary referral centre. Progression-free survival (PFS) and overall survival (OS) were the study endpoints. Principal Component Analysis and Term Frequency - Inverse Document Frequency scores were utilized for data discrimination and prediction of R>2 cm from computed tomography pre-operative reports, respectively.
No statistical significance was observed, except for age (73 vs 67 years in the no- surgery vs R2 group, : .001). Principal Components explained 34% of data variances. Reasons for no surgery included age, co-morbidities, patient preference, refractory disease, patient deterioration or disease progression, and absence of measurable intra- abdominal disease). The median PFS and OS were 12 and 14 months for no-surgery, vs 14 and 26 months for R2 (: .138 and : .001, respectively). Serous histology and performance status independently predicted PFS in both no-surgery and R2 cohorts. In the no-surgery cohort, serous histology independently predicted OS, while in the R2 cohorts, both serous histology and adjuvant chemotherapy were independent prognostic features for OS. The bi-grams "abdominopelvic ascites" and "solid omental" were amongst those best discriminating between R>2 cm and R1-2 cm.
R2 resection and no-surgery cohorts displayed unfavourable prognosis with a notable degree of uniformity. When cytoreduction results in suboptimal results, the survival benefit may still be higher compared to those who underwent no surgery.
细胞减灭术对于晚期上皮性卵巢癌(EOC)实现最佳肿瘤清除至关重要。尽管已尽最大努力,但一些患者可能经历R2(>1 cm)切除,而另一些患者可能根本未接受手术。我们旨在比较接受R2切除的晚期EOC患者与未接受手术的患者之间的结局。
在英国一家三级转诊中心,对2015年1月至2019年12月期间51例行R2切除的患者与122例未接受手术的患者的回顾性数据进行比较。无进展生存期(PFS)和总生存期(OS)为研究终点。主成分分析和词频-逆文档频率评分分别用于数据判别和根据术前计算机断层扫描报告预测R>2 cm。
除年龄外(未手术组与R2组分别为73岁和67岁,P = 0.001),未观察到统计学显著性。主成分解释了34%的数据方差。未进行手术的原因包括年龄、合并症、患者偏好、难治性疾病、患者病情恶化或疾病进展以及无可测量的腹腔内疾病)。未手术组的中位PFS和OS分别为12个月和14个月,而R2组分别为14个月和26个月(P分别为0.138和0.001)。浆液性组织学和体能状态在未手术组和R2组中均独立预测PFS。在未手术组中,浆液性组织学独立预测OS,而在R2组中,浆液性组织学和辅助化疗均为OS的独立预后特征。双词“腹盆腔腹水”和“实性网膜”是区分R>2 cm和R1-2 cm的最佳词汇之一。
R2切除组和未手术组显示出不良预后,且具有显著的一致性。当细胞减灭术结果不理想时,与未接受手术的患者相比,生存获益可能仍然更高。